SCHEDULE 13G/A 0000904454-24-000538 0000200406 XXXXXXXX LIVE 1 Common Stock, $0.001 par value 09/30/2025 0002012593 Rapport Therapeutics, Inc. 75383L102 99 High Street Suite 2100 Boston MA 02110 Rule 13d-1(d) JOHNSON & JOHNSON NJ 0.00 1784517.00 0.00 1784517.00 1784517.00 N 4.9 CO Johnson & Johnson Innovation - JJDC, Inc. DE 0.00 1784517.00 0.00 1784517.00 1784517.00 N 4.9 CO Rapport Therapeutics, Inc. 99 High Street, Suite 2100, Boston, MA 02110 This Amendment No. 1 to Schedule 13G is filed by Johnson & Johnson, a New Jersey corporation ("J&J") and Johnson & Johnson Innovation-JJDC, Inc., a Delaware corporation ("JJDC"). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC and J&J may be deemed to indirectly beneficially own such securities. Reference is hereby made to the Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Common Stock of the Issuer on October 18, 2024 ("the "Schedule 13G"). The agreement between the Reporting Persons to file jointly (the "Joint Filing Agreement") was filed as Exhibit A to the Schedule 13G. J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933 JJDC: 410 George Street, New Brunswick, NJ 08901 J&J: NJ JJDC: DE Y The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. Percentage ownership is based on 36,497,920 shares of Common Stock outstanding as of August 4, 2025, as reported in the Issuer's Report on Form 10-Q for the period ended June 30, 2025 filed with the Securities and Exchange Commission on August 7, 2025. The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. The information requested in this item is incorporated herein by reference to the cover pages to this Schedule 13G. N Y Y Y Y Y Y JOHNSON & JOHNSON /s/ Marc Larkins 10/22/2025 Johnson & Johnson Innovation - JJDC, Inc. /s/ Jill McManus 10/22/2025